EKF Diagnostics Holdings PLC Notice of Results and Investor Presentation (3991R)

TIDMEKF

RNS Number : 3991R

EKF Diagnostics Holdings PLC

01 March 2023

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Notice of Preliminary Results and Investor Presentation

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business , will announce its preliminary results for the year ended 31 December 2022, on Tuesday 28 March 2023.

Investor Presentation

Julian Baines, Executive Chair, and Marc Davies, Chief Financial Officer, will be hosting a live online presentation relating to the preliminary results via the Investor Meet Company platform at 4.30 pm on Tuesday 28 March 2023. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation here: https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor

Investors who already follow EKF on the Investor Meet Company platform will automatically be invited.

A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

 
EKF Diagnostics Holdings plc                                  www.ekfdiagnostics.com 
Julian Baines, Executive Chair / Marc                       Tel: [phone] 
 Davies, CFO 
 
Singer Capital Markets (Nominated Adviser &               Tel: + 44 ( 0)20 7496 3000 
 Joint Broker) 
Aubrey Powell / George Tzimas / Oliver 
 Platts 
 
Walbrook PR Limited                   Tel: [phone] or [e-mail] 
Paul McManus / Lianne Applegarth          Mob: [phone] 
                                                                                 303 
 
 

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:

 
 Point-of-Care            Providing a portfolio of Point-of-Care analysers 
                           and consumables, particularly for use in the area 
                           of Hematology and Diabetes, for use in hospital and 
                           research laboratories, doctor's offices, blood banks 
                           and for in-field anaemia screening programmes. EKF 
                           has an estimated 80,000 hemoglobin, hematocrit, HbA1c, 
                           glucose and lactate analysers in regular use across 
                           more than 100 countries. 
 Central Laboratory       Clinical chemistry, Small lab analysers, Centrifuges 
                           Beta-Hydroxybutyrate (<BETA>-HB) LiquiColor , Glycated 
                           Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin 
 Life Sciences            Enzyme fermentation, Custom products and Bulk fermentation 
 Contract Manufacturing   Bulk formulation, Sample collection kits, Private 
                           labelling, Molecular and forensic kits 
 Laboratory Testing       Laboratory testing services certified under the Clinical 
                           Laboratory Improvement Amendments ("CLIA") for high 
                           complexity testing. 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORSELFWAEDSEFE

(END) Dow Jones Newswires

March 01, 2023 02:00 ET (07:00 GMT)